1	Inflammation in Systemic Vascular Disease: What can we learn? Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center for Cardiovascular Disease Prevention Brigham and Women’s Hospital, Boston, MA
2
3
4
5	Pro-Inflammatory Pathways
6
7	hs-CRP and Risk of Future MI and CVA in Apparently Healthy Men
8	hs-CRP and Risk of Future Cardiovascular Events in Apparently Healthy Women: Low-Risk Subgroups
9
10	Novel Risk Factors as Predictors of Peripheral Arterial Disease
11	A Direct Comparison of LDL-C and CRP in the Prediction of First Ever Cardiovascular Events Among 27,939 Women
12
13	CRP Adds Prognostic Information at all Levels of LDL-C and at all Levels of the Framingham Risk Score
14	hsCRP Adds Prognostic Information Beyond the Framingham Risk Score in ALL Major Cohorts Evaluated
15	Clinical Predictive Value of Very Low as Well as Very High Levels of hsCRP
16
17
18	Combined Use of CT Calcium Scores and CRP in the Prediction of Cardiovascular Events: South Bay Heart Watch
19	hsCRP Predicts Onset of First Ever Stroke / TIA Independent of Other Risk factors: The Framingham Heart Study
20	hsCRP and Progression of Cerebral Small-Vessel Disease: The Rotterdam Scan Study
21	hsCRP and SAA Predict Short-Term Progression of Atherosclerosis Lesions in Human Carotid Arteries
22	hsCRP and Subsequent Development of Vascular Dementia: The Honolulu-Asia Aging Study
23
24
25	CRP, IL-6 and the Risk for Developing Type-2 Diabetes in the Women’s Health Study
26
27
28
29
30
31	hsCRP and the Development of Metabolic Syndrome or Diabetes: 11 Year follow-up Kuopio, Finland Laaksonen et al, Diabetolgia 2004;47:1403-1410
32	Moving Toward an hs-CRP Modified Definition of Metabolic Syndrome Waist circumference > 102 cm (men), > 88 cm (women) TG > 150 mg/dL or HDL < 40 mg/dL (men), < 50 mg/dL (women) SBP > 130 mm Hg or DBP > 85 mm Hg FPG > 100 mg/dL hsCRP > 3 mg/L
33	Prevalence of Conventional Risk Factors in Patients with Coronary Heart Disease (N = 87,869)
34	Moving Toward an hs-CRP Modified Framingham Risk Score
35
36	hsCRP Enters Global Risk Prediction Models Before TC, HDL, and LDLC
37
38	The Clinical Issue: Comparison of Observed vs Expected Risks With and Without hsCRP
39
40
41
42	Therapeutic Implications: hs-CRP Exercise Weight loss Smoking Cessation Blood pressure control Diet / Glucose control Lipid Reduction Targeted anti-inflammatory therapies
43	Anti-Inflammatory Effects of Statins
44
45	Inflammation, Statin Therapy, and hsCRP: Initial Observations
46	First Acute Major Coronary Event : AFCAPS/TexCAPS
47
48
49
50
51
52
53
54
55
56	REVERSAL: Regression of Atherosclerosis On Statin Therapy Occurs Primarily Among Those with Both LDL and CRP Reduction
57	Death through 2 yrs
58	Does Lowering hsCRP Correlate with Improved Vascular Risk?
59
60	Markers of Inflammation in the Prediction of Cardiovascular Disease in Women
61
62
63
64
65	Direct Evidence of Proatherogenic Effects of CRP? Aortic Atherosclerotic Lesion Size is Increased in Male CRPtg+ Apo-E Deficient Mice
66
67
68
69	Association of Common CRP SNPs with Plasma CRP Levels
70
71	Can we directly inhibit CRP function? Anti-sense drug technologies (ISIS Pharmaceuticals) Celecade / Apoptosis Approaches (Vasogen, Inc) 1-6-bis(phosphocholine)-hexane (Pentraxin Therapeutics)
72
73	Nature April 27, 2006 Pepys et al Nature 2006;440:1217-1221 Targeting C-reactive protein for the treatment of cardiovascular disease (1,6-bis(phosphocholine)-hexane)
74
75
76
77
78
79
80
81
82
83	Inflammation in Pulmonary Arterial Hypertension Dorfmuller, Perros, Balabanian, Humbert Eur Respir J 2003;22:358-363 Does Inflammation play a role in some forms of PH? Monocrotaline-induced PH Scleroderma, lupus, mixed connective tissue disease HIV POEMS (plasma cell dyscrasia, organomegaly, endocrinopathy, monoclonal protein, skin changes)